In his latest interview with iconic physicians in urology, uro-oncology, and related fields, Grand Rounds in Urology (GRU) contributing editor Neil H. Baum, MD, interviews Bela Denes, MD, Vice President of Global Medical Affairs at Lantheus Medical Imaging, focusing on his remarkable career in the pharmaceutical and medical device industries after his time as a practicing clinician. Dr. Denes reflects that his transition from clinical practice to industry giants like Amgen, Eli Lilly, and Pfizer, was driven by various factors, including the recognition of burnout among colleagues in clinical practice and a desire for new opportunities.
Dr. Denes discusses the evolving landscape of drug development and the increasing need for urology expertise in the pharmaceutical industry. He emphasizes the importance of clinical experience in understanding diseases, patient management, and designing effective studies.
Dr. Denes also shares insights into the challenges and rewards of working in the industry, including the long-term impact of industry contributions and the benefits of learning about regulatory pathways and drug approval processes. Dr. Denes highlights the differences between device regulatory pathways and drug development. He discusses the potential advantages of single-use cystoscopes, such as cost-efficiency, convenience, and reduced environmental impact. He predicts that economics and environmental considerations will play a significant role in the adoption of single-use instruments in urology.Read More